Inactive Instrument

Trillium Therapeutics Stock price

Equities

TRIL

CA89620X5064

Dynamic Chart
TCR2 Therapeutics Appoints Chief Business and Strategy Officer MT
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis DJ
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover MT
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index CI
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition MT
Trillium Therapeutics Inc. Announces Executive Changes CI
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer CI
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer CI
Benchmark Downgrades Trillium Therapeutics to Hold From Buy MT
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval MT
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index CI
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others. CI
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
North American Morning Briefing : Stock Futures -3- DJ
Trillium Therapeutics Brief: Says Received Final Court Order Approving Arrangement With PF Argentum ULC, a wholly-owned, indirect subsidiary of Pfizer Inc MT
More news
Managers TitleAgeSince
President 55 21-11-16
Chief Tech/Sci/R&D Officer 64 18-12-31
Director/Board Member - 21-11-16
Members of the board TitleAgeSince
President 55 21-11-16
Director/Board Member - 21-11-16
More insiders
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don?t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium's second SIRP?Fc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRP? as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Trillium Therapeutics - Toronto S.E.